Key IMPAACT Treatment Studies

IMPAACT HIV Treatment Scientific Committee Update at the IMPAACT Community and Science Session

Theodore Ruel, MD
23 June 2022

ANNUAL MEETING
2022

History of Dolutegravir



2009

IMPAACT P1093 protocol discussions begin

2011

IMPAACT P1093 FSFV April 2011

2012

Pediatric Granules 1st batch delivered to GSK (December)

2013

Approval of Adolescent Indication 50mg With original Tivicay submission (Aug)

Development of dispersible tablet technology commenced in parallel

2014

Difficulties with granule had become apparent

2016

Dispersible Tablet First introduced into P1093;

2019

Regulatory submission made to EMA and FDA Tivicay 5mg Dispersible Tablet >3kg and 50mg film coated tablet down to 20kg

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Approvals and roll-out …

12 June 2020

13 Jan 2021

18 June 2020

<u>Tivicay 5 mg dispersible tablets regulatory Approvals granted to date:</u>
US FDA, EU EMA, Australia, Botswana, Brazil, Canada, Chile, Ghana, Kazakhstan, Malawi, Namibia, Switzerland, Tanzania, United Kingdom, Uruguay, Zimbabwe

<u>Viatris (formerly Mylan) generic 10 mg dispersible tablet - Clinton Health Access group:</u>
Thailand – Submitted September 2021
Brazil – no submission plans at this point
South Africa – Submitted June 2021
Botswana – Submitted March 2021
Zimbabwe – APPROVED August 2021
Kenya – Submitted December 2020
Uganda – Submitted January 2021

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Dolutegravir for neonates

Protocol in development!

Study No.	Study Name	Population
2023	Safety, Tolerability, & PK of **Dolutegravir in Neonates** Exposed to HIV-1	Infants born to mothers living with HIV

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Study Highlight: IMPAACT 2019

ABC/DTG/3TC as Fixed-Dose Combination for Children

- New fixed-dose, dispersible, once-a-day combination for young children
- Fully enrolled during COVID-19 pandemic; pending confirmation of completion of final visits
- 57 participants enrolled at 14 sites in Botswana, Thailand, South Africa, and United States
- Anticipate primary publication soon

Small child drinking syrup from disposable cup, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Two studies currently closed to accrual, completing follow-up, within the Treatment Research Area

Study No.	Study Name	Population
2019	Pharmacokinetics, Safety, & Tolerability of **Abacavir/Dolutegravir/Lamivudine** Dispersible and Immediate Release Tablets **in Children** Less than 12 Years of Age Living with HIV-1	Infants and children living with HIV
P1093	Safety, Tolerability & Antiviral Activity of **Dolutegravir** Combination Regimens in **Infants, Children and Adolescents Living with HIV-1**	Infants, children, and adolescents living with HIV

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Injectable Cabotegravir and Rilpivirine

- 2 muscular infections
- Every 1 or 2 months
- FDA Approved January 2021





IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Study Highlight: IMPAACT 2017

Safety & PK of Long-Acting Injectable Cabotegravir & Rilpivirine

- First study of long-acting injectable regimens in adolescents with HIV
- 103 adolescents and 10 parents/ caregivers enrolled at 16 sites in Botswana, South Africa, Thailand, and the US

Anticipate completing accrual by September 2022

Teenagers in a line, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

IMPAACT 2017 (MOCHA) Data Informs U.S. FDA Approval of Cabenuva for HIV Treatment in Virologically Suppressed Adolescents

MARCH 2022 | ANNOUNCEMENTS

SHARE

The IMPAACT Network is pleased to announce that interim data from IMPAACT 2017/MOCHA (More Options for Children and Adolescents) has informed the U.S. Food and Drug Administration's (FDA) decision to approve Cabenuva (cabotegravir, CAB; rilpivirine, RPV) for the treatment of HIV-1 in adolescents who are virologically suppressed, 12 years of age or older, and weigh at least 35 kg. Adolescents must be on a stable antiretroviral regimen with no history of treatment failure, and with no known or suspected resistance to either

First time a long-acting HIV treatment is available for adolescents

ViiV Healthcare

ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF *CABENUVA* (CABOTEGRAVIR, RILPIVIRINE) FOR VIROLOGICALLY SUPPRESSED ADOLESCENTS LIVING WITH HIV WHO ARE 12 YEARS OF AGE OR OLDER AND WEIGH AT LEAST 35 KG

Study in Development: IMPAACT 2040

PK & Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in People with Virally Suppressed HIV-1 during Pregnancy and Postpartum

- Continued successful collaboration from IMPAACT 2017 and 2036 with ViiV/Janssen to study long-acting, injectable regimens
- Enrolling participants who are pregnant and living with HIV (and their infants)

Anticipate protocol to sites by May 2023

Group of people who are pregnant, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Study in Development: IMPAACT 2036

Safety & PK of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children with HIV

- Continued successful collaboration from IMPAACT 2017 with ViiV/Janssen to study long-acting, injectable regimens in children
- Children will be two to less than 12 years old
- Planned at 12 sites in Brazil, Botswana, South Africa, Thailand, Uganda, and the US

Anticipate protocol to sites by September 2022

Child with celebratory soccer/football gear, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Study in Development: IMPAACT 2037

Safety and PK Parameters of Potent Anti-HIV Neutralizing Monoclonal Antibodies

- Building on work from IMPAACT P1112, evaluating two potent anti-HIV neutralizing monoclonal antibodies
- Will be administered soon after birth to infants at high risk for peripartum or breastfeeding HIV transmission

Anticipate protocol to sites by Q4 2022

Clinician administering shot to infant on lap, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Other study currently enrolling within the Treatment Research Area

Study No.	Study Name	Population
2026	PK Properties of **Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum**	Pregnant and postpartum women and their infants

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

One protocol recently closed to follow-up within the Treatment Research Area

Study No.	Study Name	Population
2014	PK, Safety, & Tolerability of **Doravirine** and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate **in Adolescents Living with HIV**	Adolescents living with HIV

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Study Highlight: IMPAACT 2014

Doravirine as Fixed-Dose Combination for Adolescents

Closed to follow-up and POS/PAC 25 May 2022

- New fixed-dose, one-pill/once-a-day combination for adolescents
- 55 participants enrolled at 8 sites in South Africa, Thailand, and the US in Cohort 2
- Data informed recent US FDA and EMA decisions to approve DOR and fixed-dose combination of DOR/3TC/TDF in adolescents living with HIV

Group of adolescents inside, Getty Images

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Treatment Scientific Committee Membership

Chair & Vice Chair: Ted Ruel and Mo Archary				
At-large Members			**LOC Members**	**NIH Members**
Linda Barlow-Mosha	Brookie Best	Carolyn Bolton Moore	**Katie McCarthy**	Renee Browning
Edmund Capparelli	Diana Clarke	Lee Fairlie	Sharon Nachman	Fadzi Kasambira
Liz Lowenthal	Mark Mirochnick	Jorge Pinto	Veronica Toone	Ellen Townley
Andy Wiznia			Michael Whitton	Dwight Yin

SBS Core	**CAB Members !!!**	**LC Member**	**SDMC Members**
Rivet Amico	**Aisha Gava**	Helty Adisetiyo	Sean Brummel
Rachel Kidman	**Thabo Makete**		Mae Cababasay
			Barb Heckman

Questions?
Suggestions?

IMPAACT
International Maternal Pediatric Adolescent AIDS Clinical Trials Network

THANKS!